<DOC>
	<DOC>NCT00627445</DOC>
	<brief_summary>This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.</brief_summary>
	<brief_title>Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months HbA1c (Glycosylated Haemoglobin A1c) between 7.5% 12.0% (both inclusive) FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L BMI (Body Mass Index) 2340 kg/sq.m (both inclusive) Metformin contraindications according to local practice Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>